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Summary 
The mechanisms that regulate the commitment of a totipotent stem cell to the megakaryocytic 
lineage are largely unknown. Using a molecular approach to the study of megakaryocytopoiesis 
and platelet production, mice in which thrombocytopoiesis could be controlled were produced 
by targeting the expression of the herpes simplex virus thymidine kinase toxigene to megakaryo- 
cytes using the regulatory region of the gene encoding the c~ subunit of the platelet integrin 
cdIbB3. The programmed eradication of the megakaryocytic lineage was induced by treating 
transgenic mice bearing the hybrid construct (odlbtk) with the antiherpetic drug ganciclovir 
(GCV). After 10 d of treatment, the platelet  number was reduced by >94.6%.  After discon- 
tinuing GCV, the bone marrow was repopulated with megakaryocytes and the platelet count 
was restored within 7 d. Prolonged GCV treatment induced erythropenia in the transgenic mice. 
Assays of myeloid progenitor cells in vitro demonstrated that the transgene was expressed in 
early erythro-megakaryocytic progenitor cells. The reversibility and facility of this system pro- 
vides a powerful model to determine both the critical events in megakaryocytic and erythroid 
lineage development and for evaluating the precise role that platelets  play in the pathogenesis 
of a number of vascular occlusive disorders. 
T 
he  differentiation of myeloid cells  requires  a  highly 
complex  series of cellular  events  in  which  a  small 
population of stem cells generates large populations of ma- 
ture cells and culminates in the production of circulating blood 
cells. The molecular mechanisms regulating the proliferation 
and differentiation of the pluripotent hematopoietic stem cell 
involve interactions between stromal elements and a wide va- 
riety of inducing and inhibitory cytokines. Previously, in vitro 
clonal  assays as  well  as  in  vivo  studies of bone marrow 
(BM) t  cells have suggested a unifying hierarchical  model 
that implicates the commitment of a particular stem cell to 
specific lineages via a progressive loss of its pluripotentiality 
1  Abbreviations used in this  paper: ACHE, acetyl cholinesterase; BM, bone 
marrow; BFU-E, erythroid burst-forming unit; CFU-GEMM, granulo- 
monocytic-erythroid-megakaryocytic  CFU;  CFU-MK,  megakaryocyte 
CFU;  EM,  erythroid megakaryocytic; GM-CFC, granulocytic colony- 
forming cells; EPO, erythropoietin;  GCV, ganciclovir; MGG, May- 
Grfinwald Giemsa; rHu, recombinant human; rMu, recombinant routine; 
RT-PCR, reverse transcriptase PCR;  tk,  thymidine kinase. 
(reviewed in reference 1). This model is supported by the ob- 
servation that several types of multilineage colonies of vari- 
able phenotypes can develop directly from a unique totipo- 
tent  stem  cell under  the  influence  of a  range  of specific 
cytokines. The existence of such colonies has been documented 
in mice (2-4) and humans (5-7).  The genetic mechanisms 
controlling the commitment and diversification  of cellular 
lineages, however, are poorly understood. This is particularly 
the case in megakaryocyte development, which entails  the 
commitment and proliferation of progenitor cells, matura- 
tion,  and endomitosis, culminating in  the production of 
platelets. 
Most of the studies on megakaryocyte development have 
been performed on ex vivo models using semisolid or liquid 
culture systems (8, 9). These techniques, however, have their 
limitations. They do not result in platelet  production, and 
gene transfer experiments are not feasible because of the low 
representation of megakaryoeytes in BM. In addition, the ab- 
sence of the microenvironment does not permit the analysis 
of the involvement of both known and unknown factors that 
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tribution of accessory stromal cells. Thus, a molecular genetic 
approach addressing the mechanisms that regulate megakaryo- 
cytopoiesis requires  in vivo studies with appropriate animal 
models. 
With this in mind, our approach  has been to target the 
expression  of a toxic gene into megakaryocytes of mice to 
provide  the  means by which platelet  production may be 
modified on demand. The successful application  of a number 
of toxigenes as reverse genetic tools in transgenic mice has 
been reported.  Bacterial  protein toxins,  such as diptheria, 
cholera, and more recently, tetanus, have been used to eradi- 
cate acinar pancreatic cells (10), induce pituitary hyperplasia 
and gigantism (11), and disrupt spermatogenesis (12). Al- 
though the number of transgenic animals described in these 
studies was apparently normal, the small number of trans- 
genic founders reported in other studies suggests that early 
lethality may occur because of transient expression of the trans- 
gene in the embryos after microinjection. An alternative ap- 
proach would be to use genes that are not themselves  toxic, 
but sensitize  the targeted cells to the effects of drugs. This 
is the case for the thymidine kinase (tk) gene of HSV-1. Un- 
like mammalian tk, HSV tk is capable of phosphorylating 
nucleoside analogues, like ganciclovir (GCV), leading to the 
inhibition of DNA synthesis in dividing cells (13, 14). This 
approach has the advantages of its ease of administration and 
reversibility. Hematopoiesis is a particularly good system for 
the application of this cell suicide technique because it allows 
the monitoring of a particular cell type during a complex 
program of cell differentiation. 
The odlb gene has been shown to be an early marker of 
megakaryocytopoiesis, and it encodes  the t~ subunit of the 
platelet integrin c~IIb33 (15). This molecule functions as a 
receptor for adhesive proteins and is involved in platelet adhe- 
sion (16). While the 33 subunit is synthesized in different 
tissues, the c~IIb subunit is expressed only in megakaryocytes. 
It has been shown that the gene is active at an early stage 
of megakaryocyte differentiation (17) and an 813-bp DNA 
fragment located upstream of the initiation start site of the 
oelIb gene contains cis-acting elements necessary for lineage 
specific expression in vitro (18, 19). Thus, the regulatory ele- 
ments of the otlIb gene were used to target the expression 
of the tk gene to early megakaryocyte progenitors of trans- 
genic mice. The injection or withdrawal of GCV was shown 
to result in a rapid, severe, and reversible thrombocytopenia. 
Materials  and Methods 
Recombinant DNA  Construct.  The plasmid pBKtk-1 (20) was 
digested by BamH1 and blunted. The 3,290-bp DNA fragment 
containing the HSV-1 tk gene was further digested by HinclI to 
delete the regulatory sequences of the virus, and it was inserted 
into the EcoR V site of pBluescript (Stratagene, La Jolla, CA), 
giving the plasmid ptkH. The human cdlb promoter region, ex- 
tending from + 33 to - 787 relative to the initiation start site, was 
excised from the plasmid IIbpBLCAT3 (18) and inserted in the 
HinclI site of ptkH. The resulting plasmid was digested by SacI 
to excise the 3,599-bp fragment containing the entire cdIbtk gene. 
For in vitro studies, this fragment was blunted and inserted into 
a blunt-ended SalI-digested  pCEP4 plasmid (Invitrogen, San Diego, 
CA), an episomal vector containing the hygromycin B resistance 
gene. For the production of transgenic animals, the 3,599-bp DNA 
fragment was microinjected directly into fertilized eggs. 
DNA  Transfections.  HEL, K562, U937, and HeLa cells were 
grown in RPMI 1640 medium (GIBCO BR.L, Gaithersburg, MD) 
containing  10%  FCS  and  antibiotics (streptomycin/penicillin) 
(Boehringer Mannheim GmbH, Mannheim, Germany) and trans- 
fected by electroporation, using a gene pulser (Bio Rad Laborato- 
ties, Hercules, CA). Each assay  was done with 10/~g of the txlIbtk 
DNA. Cells were grown in RPMI medium supplemented with 
10% FCS and antibiotics. After 24 h, hygromycin (50/zg/ml) was 
added to the medium. The expression of the transfected  DNA was 
analyzed by the reverse transcriptase PCR (RT-PCR) method ei- 
ther 48 h after electroporation or after 3 wk of hygromycin  B selec- 
tion. The cytotoxicity of the nucleoside  analogue GCV was deter- 
mined in vitro on cdlbtk stable transformed cells obtained after 
3 wk of hygromycin B selection. Various concentrations of GCV 
(ranging from 0 to 200/zM) were added to the culture to assess 
the toxicity of the antiherpetic drug on cdlbtk-transfected HEL 
cells since it has been found that there are significant differences 
in the sensitivity to GCV between various cell types (21). 
Production and Screening of Transgenic  Mice.  The otlIbtk construct, 
without any vectorial sequences, was microinjected, using estab- 
lished procedures (22), into fertilized eggs resulting from mating 
between C57/SJL mice. Transgenic offspring were identified by 
Southern blot analysis  (23) using genomic DNA (10/zg) extracted 
from tail samples. DNA was digested with PvulI,  separated on 
a 0.8% agarose gel, transfered to Hybond N § (Amersham Inter- 
national plc, Bucks, UK) and hybridized with a random-primed 
(24) tk probe. 
RNA  Isolation.  Total  RNA was prepared from pelleted BM 
cells using a rapid total RNA isolation kit (5 Prime-3 Prime, Inc., 
Boulder, CO). RNA isolation from tissues was performed as pre- 
viously described (22). 
RT-PCR.  5 gig of total KNA were first treated with 1 U of 
RQ1 DNase (Promega Corp., Madison, WI) and then denatured 
(70~  for 10 min) before it was used as a template in a 40-/~1 cDNA 
synthesis reaction using random hexanucleotides. 5/zl of the re- 
verse transcription mixture were amplified  by PCR (25) in a ther- 
mocycler (PHC-3; Techne  Corp., Cambridge, MA). PCR reactions 
were performed under standard Perkin-Elmer  Cetus conditions, for 
40 cycles (94~  1 rain, 55~  1 rain, 72~  1 min), followed by 
3 min at 72~  PCR products were run through a 1.5% agarose 
gel and transfered to Hybond N §  Filters were hybridized with 
end-labeled internal specific  oligonucleotides.  Routine controls per- 
formed in each experiment included a eDNA  reaction mixture 
without addition of reverse transcriptase as a check against genomic 
DNA contamination and a PCR control with no template added 
to control for PCR artifacts caused by contamination. 
In Vivo GCVAdministration.  GCV (CYMEVAN; Syntex, Palo 
Alto, CA) was administrated twice a day by intrapetitoneal (i.p.) 
injection over different time intervals as described later. The dose 
of GCV was 0.05 mg/d per g body wt. 
Oligonucleotide Synthesis and PCR Primers.  Oligonucleotides  used 
as primers for PCR were synthesized  on a DNA synthesizer  (381A; 
Applied Biosystems, Inc., Foster City, CA). The 5' tk primer was 
CCCCTGCCATCAACACGCGT  and  the  3'  tk  primer  was 
CGGCGTCGGTCACGGCATAA  nucleotides  529-543  and 
929-910 from the tk sequence, respectively  (26). The 5' alIb primer 
was GGAAGATGGCCAGAGC  nucleotides 22-43 and the 3' alIb 
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tides 4,013-4,032  (27). 
Growth  Factors.  Pure recombinant routine (rMu) stem cell factor 
and rMuGM-CSF  were purchased from Genzyme Corp.  (Cam- 
bridge, MA). Pure recombinant human (rHu) GM-CSF and pure 
rHu erythropoietin (EPO) were purchased from Boehringer Mann- 
heim. Pure rMulL-3 and rHulL-6 were purchased from PeproTech, 
Inc.  (Rocky Hill,  NJ). 
CelIPreparation.  BM was flushed from the femoral cavity with 
IMDM supplemented with PG-E1 using a syringe with a 25-gauge 
needle.  BM cells were separated from the core matrix by manual 
pipeting and were washed twice in PBS. 
Megakaryocyte  Progenitors  (CFU-MK).  BM cells were cultured 
in triplicate in 35-ram petri dishes (Falcon Labware, Oxnard, CA) 
in serum-free conditions (1.5  x  1@ cells per well) in I ml IMDM 
supplemented with various ingredients used in serum-free cultures 
as previously reported (9), with the exception that 0.3% agar (Difco 
Laboratories, Detroit, MI) was substituted for methylcellulose.  The 
growth of CFU-MK was stimulated with 50 ng murine 1I.,3 and 
5 ng Ib-6/ml. After 7 d  of incubation in a COz incubator (5% 
CO2 in air, 37~  the agar discs  were harvested, dessicated on 
large glass slides, and stained for the megakaryocytic-specific acetyl 
cholinesterase  (ACHE) activity (28). 
Erythroid Burst-forming Units  (BFU-E).  BM cells (5  x  104 cells 
per  well)  were  cultured  in  triplicate  plastic  dishes  (Nunclon, 
Roskilde, Denmark) in 0.25 ml of IMDM supplemented with 20% 
FCS (Seromed, Berlin,  Germany), 1% deionized BSA (Sigma Im- 
munochemicals, St. Louis, MO), 300/~g/ml transferrin fully satu- 
rated  with  FeC13 (Boehringer  Mannheim),  10  /~g/ml  insulin 
(Sigma), 0.2 mM crystalline bovine hemin (Sigma),  10 -4 M mono- 
Figure  1.  In vitro analysis of odlbtk gene function. (A) Diagram of the recombinant plasmid used for transfection. The Sail fragment of the pCEP4 
containing the CMV promoter was replaced by the c~Ilbtk gene excised from pBluescript by SacI digestion.  The Kpnl (K), Xhol (0), XbaI Of), 
BamHl (B), and NotI (N) restriction sites of pBluescript are represented. (B) PCR analysis performed on RNA prepared from HEL cells transfected 
with CMVtk or odlbtk in the presence (+) or absence (-) of reverse  transcriptase: (lane 1 ) amplification with the 5' odlb primer and the 3' tk primer, 
(lane 2) amplification with 5' and 3' tk primers, and (lane 3) amplification performed with 5' and 3' c~Ilb  primers. (C) Inhibition of cellular growth 
by GCV in ~Ilbtk transfected cells. 
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rHuG-CSF, and 2 U of EPO. The dishes were incubated for 7-8 d 
at 37~  in a fully humidified incubator  flushed with 5% CO2. 
The dishes were examined  under an inverted microscope.  GM-CFC, 
BFU-E, CFU-MK, and various mixed progenitors including CFU- 
GEMM were identified and counted. The nature of mixed progen- 
itors was controlled by picking up the colonies from the methyl- 
cellulose using an Eppendorf pipette. The colonies were smeared 
on glass slides, stained with May-Gr~inwald Giemsa (MGG), and 
examined microscopically. 
Cell Counting Procedures.  Blood was collected from tail vein 
bleeds into acid citrate dextrose containing  PG-E1 (10/~M),  7:1 
blood/anticoagulant  (vol/vol).  All cell counts  were determined 
manually using a counting chamber and microscopy. Erythrocytes 
were counted after dilution (1:200) in PBS, whereas leukocyte and 
platelet counts were performed after dilution (1:20) in Thrombo- 
Zahl solution  (Merck, Darmstadt,  Germany).  The mean values 
(n  =  10) for the control nontransgenic  animals by this method 
were: platelets  =  0.94  _+  0.24  ￿  1012/liter  (SD), leukocytes = 
10.19  _+  3.11  x  109/liter (SD), erythrocytes  =  10.45 _+  2.13 x 
10n/liter  (SD), and they were within the normal range for non- 
transgenic mice (29, 30). 
Figure  2.  Development  of mice transgenic  for cdlbtk. (A) Schematic 
illustration of the cdlbtk construct.  The restriction  map shows the Pvull 
sites and the size  (bp) of  the restriction  fragments.  (B) Southern  blot anal- 
ysis of DNA prepared  from the four founders. As expected, a 2,213-bp 
fragment was observed  after PvulI digestion and hybridization  with the 
tk probe. A second  expected 1,382 fragment was obtained  when several 
transgenes are positioned in a head to tail conformation.  Mice numbers 
1, 2, 3, and 4 had integrated  6, 10, 1, and 3 copies  of  the transgene, respec- 
tively. 
thioglycerol, and 1.2% methylcellulose (Fluka AG, Buchs, Swit- 
zerland). The growth of BFU-E was  stimulated  with  1 ng of 
rMulb3 and 1 U of EPO. The cultures were examined after 8 d 
and aggregates of >100 red cells were considered as a BFU-E. 
Granulomonocytic  Colony-forming  Cells  (GM-CFC).  BM cells were 
cultured in triplicate (5  x  104 cells per well) in 0.25 ml IMDM 
supplemented with 20% FCS, 1% deionized BSA (Sigma), 10 -4 M 
monothioglycerol, and 1.2% methyl-ceUulose.  The growth of GM- 
CFC was stimulated by 10 ng/ml rMuGM-CSF. After 7 d of incu- 
bation at 37~  in a CO2 incubator flushed with 5% CO2 in hu- 
midified air, aggregates of at least 50 cells were considered to be 
GM-CFC. 
Mixed Progenitors  and Granulo-Monocytic-Erythroid-Megakaryocytic 
CFU (CFU-GEMM).  CFU-GEMM were cultured in quadrupli- 
cate in 35-mm petri dishes containing 5  x  104 BM ceils in 1 ml 
of culture medium that had the same composition as that used for 
BFU-E. The growth of mixed colonies  was stimulated by 50 ng/ml 
Results 
Analysis of the alIbtle Hybrid Gene Function.  The odlbtk 
plasmid,  in which HSV-1  tk expression is directed by 813 
bp of regulatory sequences of the megakaryocytic specific pro- 
moter o~IIb, was introduced into plasmid pCEP4. Thig is an 
episomal vector for expression of  foreign genes in mammalian 
cells that contains the hygromycin B gene as the selectable 
marker (Fig.  1 A).  To establish whether the expression of 
the construct was  tissue specific,  transient transfections of 
the pCEP4-cdlbtk were performed in megakaryocytic and 
nonmegakaryocytic cell lines.  Tk transcripts were detected 
only in the transfected HEL megakaryocytic cell line as de- 
termined by KT-PCR of mKNA using tk-specific primers 
(Fig.  1 B). The U937 monocytic cell line, the HeLa epithe- 
lial cell line, the K562 erythroleukemic cell line, and the non- 
transfected HEL cells did not demonstrate any detectable tk 
mRNA.  In contrast, when the IIb promoter was replaced 
by the CMV  promoter, tk transcripts were detected in all 
the cell types examined (data not  shown). 
To test for the function of the expressed protein and the 
toxic potential of the hybrid gene in vitro,  stable cultures 
of HEL expressing tk were generated after 3 wk of hygro- 
mycin-B selection, At this stage,  10  s cells were cultivated in 
the presence of different concentrations of GCV for an addi- 
tional 6-d period. As shown in Fig. 1 C, only the transfected 
cells expressing the oelIbtk gene demonstrated reduced growth, 
while nontransfected HEL cells were unaffected. The results 
obtained  with  both  transient  and  stable  transfected  cells 
confirmed that the hybrid gene was active in vitro and main- 
tained a tissue-specific  activity and thus was suitable for the 
production of transgenic mice. 
Generation and Characterization of Transgenic Mice.  The 
alIbtk transgene (Fig. 2 A) was excised from the pCEP4- 
ollIbtk and microinjected into fertilized eggs.  Among the 
18  offspring obtained,  4  were found  to  be  transgenic by 
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were seeded  in liquid serum free medium at a concentration of 5 x  10  s cells/ml and were cultured in the presence  or absence of 25/~M GCV. After 
a 5-d culture, megakaryocytes  were identified by AChE positivity. 
Southern blot analysis performed with the tk probe (Fig.  2 
B).  The number of integrated  copies ranged from  1 to 10, 
as determined after phosphorimager analysis of tk-hybridized 
blots. All founders transmitted the transgene to their progeny 
in a Mendelian fashion. In this study, the transgenic line de- 
rived from the founder carrying one copy of the transgene 
was analyzed. 
To test for the tissue-specific expression of the chimeric 
gene, total RNA was prepared from BM, liver, kidney, thymus, 
spleen, lung,  adrenal gland,  testis, submaxillary gland,  and 
brain of transgenic and nontransgenic  littermates.  This was 
analyzed by RT-PCR using the tk primers.  Tk mRNA was 
found in the BM, adrenal gland,  and testis.  Previously, the 
odlb promoter has not been shown to be active in these last 
two tissues. The presence oftk transcripts in the adrenal gland 
cannot  be considered  as  aberrant  expression  since  another 
megakaryocyte-specific gene, platelet factor 4, has also been 
reported to be active in this tissue (31).  The significance of 
this observation, however, remains unknown.  On the other 
hand, it was found that all constructs harboring the coding 
region of the tk gene were expressed at different levels in the 
testes of all the transgenic males, regardless of the promoter 
that was used. It was suggested that testicular expression may 
be controlled by a cryptic TATA box-independent promoter 
located in  the coding  region  of the  tk  gene  (32). 
To test the function of the tk protein produced by the trans- 
gene, the toxic effect of GCV on megakaryocytes was exam- 
ined. Cells isolated from the BM of transgenic and nontrans- 
genic  littermates  were  cultured  in  serum-free  medium 
containing GCV and supplemented with IL-3 and IL-6 to en- 
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Figure  4.  Changes  in platelet count after GCV treat- 
ment of transgenic and nontransgenic mice. Transgenic 
and nontransgenic littermates were treated with GCV 
(0.05 mg/g i.p. daily for 9 d). Platelet counts were de- 
termined on tail bleeds during and after the suspension 
of GCV treatment. Each data point shows  the mean SD 
(.  =  5). 
rich for megakaryocytes (9). The concentration of GCV used 
(25/~M) was determined on the basis of pilot studies where 
varying concentrations (0-200/zM) of GCV were evaluated. 
At the concentration chosen, no toxic effects on normal con- 
trol megakaryocytes were noted (data not shown). After 6 d 
of liquid culture,  no megakaryocytes were detected in the trans- 
genic BM culture,  as determined by the megakaryocytic-specific 
AChE method (Fig. 3). Megakaryocytes of the nontransgenic 
mice were not affected by the GCV treatment. We concluded 
that the tk gene was expressed in megakaryocytes under the 
control of the odlb promoter and its product, i.e., tk, selec- 
tively eradicates tk expressing cells in the presence of GCV. 
Effect of GCV Treatment on Blood and BM Cellularity.  To 
study the in vivo effect of GCV treatment on platelet produc- 
tion, 5-wk-old transgenic and non transgenic mice were in- 
jected i.p. with GCV (0.05 rag/day per g body wt) for 10 d. 
Blood samples were drawn from the tail vein and cell counts 
were determined by microscopy. The  mean platelet  count 
(n  =  5) in  the transgenic  mice was reduced from 0.82  ￿ 
1012 to 0.045  x  1012/liter by day 10 of GCV treatment, cor- 
responding  to  a  >94.6%  decrease  in  circulating  platelet 
number. In contrast, the platelet counts of the nontransgenic 
littermates were unaffected by the GCV treatment.  Leuko- 
cyte and erythrocyte counts were unaffected in both groups 
of animals under these conditions. When the administration 
of GCV was interrupted,  the process was reversed and the 
platelet counts had returned to normal values by 9 d (Fig.4). 
Qualitative changes in platelet morphology were observed 
by microscopy during the induction and reversal of throm- 
bocytopenia during GCV treatment and its withdrawal, respec- 
tively.  There was a gradual overall reduction in platelet size 
as thrombocytopenia developed, and this was reversed  and 
larger than normal platelets were observed during the recovery 
phase. Qualitatively, this is in line with the expected changes 
in platelet size during supression of thrombopoiesis and its 
recovery. Unfortunately, the methodology used, i.e., manual 
cell counting,  did not lend itself to accurate determination 
of mean platelet volume. In future studies, this will be ad- 
dressed using automated cell counting techniques which pro- 
vide accurate estimates of this parameter  (33). 
The precise stage of megakaryocytic differentiation  at which 
the expression of the hybrid gene appeared was next exam- 
ined in BM after  10 d  of GCV administration.  As shown 
in Fig. 5, GCV treatment resulted in a complete eradication 
of AChE-positive megakaryocytic cells from the BM of odlbtk 
mice. Surprisingly, however, microscopic examination of BM 
cytospins stained with MGG revealed that erythroid cells were 
also reduced to  1.5%  of total BM cells compared to 24% 
in GCV-treated nontransgenic mice, suggesting an increased 
sensitivity of the erythroid lineage to the drug in the trans- 
genic animals. In contrast, the myelomonocytic and lymphoid 
lines were unaffected. Although this may disagree with the 
observation that the circulating erythrocyte counts were un- 
changed after 10 d of GCV treatment, this may be explained 
by the longer half-life  of the erythrocyte, which is •25  d 
(29).  Hence, >10 d treatment  with GCV may be required 
to induce a significant decrease in the number of circulating 
erythrocytes. To test  this  hypothesis,  animals  were treated 
for 23 d and the cell counts followed. Under these condi- 
tions,  the mean erythrocyte count decreased from  10.9  ￿ 
1012 to 2.2  x  101Z/liter, but it remained unchanged in the 
treated nontransgenic mice. Similarly, the mean platelet count 
decreased from 1.2  x  10 lz to 0.016  x  1012/liter. Leukocyte 
counts were unaffected (Table  1). 
These data demonstrated that the expression of the tk gene 
in the megakaryocyte lineage induced a severe but reversible 
thrombocytopenia caused by a failure of thrombopoiesis. This 
raised the possibility that these animals might be used to assess 
the effect of cytokine administration  on platelet production. 
To evaluate  this,  the platelet kinetics of thrombocytopenic 
animals  were monitored after treatment with Ib6 and Ibll 
(0.08/zg/g per d). As shown in Fig. 6, the rate of recovery 
was increased with the administration  of Ibll,  resulting in 
complete normalization  within 2 d, whereas with IL-6, no 
improvement over untreated thrombocytopenic controls was 
noted. 
Cytotoxic Effect of GCV on Myeloid Progenitor Cells.  BM 
cells of control and c~Ilbtk mice treated for 10 d with GCV 
were cultured using individual  semi-solid progenitor cell assays. 
The number of megakaryocytic colonies was evaluated in situ 
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a  total  disappearance  (Experiment  2)  of megakaryocytic, 
erythroid, and various mixed colonies in the odlbtk BM cell 
cultures was observed. Only colonies of granulomonocytes 
and macrophages,  in numbers and size comparable to those 
observed in  nontransgenic  controls,  were seen.  These data 
were also obtained in liquid cultures  of BM cells from the 
ollIbtk mice treated with GCV in vivo, confirming the eradi- 
cation of megakaryocytic and erythroid cells but maintenance 
of granulomonocytic  cells  (data not  shown). 
Figure 5.  Effect  of GCV treatment on BM cellularity  of transgenic and 
nontransgenic mice. Transgenic and nontransgenic littermates were  treated 
with GCV (0.05 mg/d per g i.p.) for 10 d. Cytospin preparations were 
stained with MGG. xl00. (A) BM from a treated nontransgenic animal 
(B) BM from a treated cdIbtk mouse. Mature megakaryocyte  (M) and 
erythroid cells  (E) are seen in the BM of the control nontransgenic mouse 
but are absent in the transgenic animal 
on dried agar gel disks stained by the AChE  method.  The 
development of CFU-MK and BFU-E colonies in cultures 
of BM cells from GCV-treated alIbtk  mice was drastically 
affected  and  colonies  were barely  detectable,  whereas  the 
number and size of granulomonocytic colonies from the BM 
of the same mice were in the control range (Table  2). The 
inhibition of CFU-MK and BFU-E was confirmed in a sepa- 
rate set of experiments where early myeloid multipotent pro- 
genitor  cells  were tested in methyl-cellulose.  In  this  assay, 
a mixture of several hematopoietic growth factors was used 
to obtain  all  the combinations  of mixed myeloid colonies. 
Discussion 
These studies describe the generation of transgenic  mice 
in which a severe and reversible thrombocytopenia could be 
produced on demand. This inducible thrombocytopenia was 
achieved by the expression of the tk gene directed by the regula- 
tory elements of the gene encoding the platelet-specific alIb 
integrin subunit. The tk protein was toxic to the early mega- 
karyocytic progenitors, leading to a complete eradication of 
the lineage within a week. The toxic effect of GCV was re- 
versible and a normal platelet count was restored as soon as 
7 d after the termination of the GCV injections. These mice 
also developed an erythropenia when drug administration was 
maintained  for >20 d. A detailed analysis  of the toxic effect 
of the drug on the BM of GCV-treated mice showed a near 
total  inhibition  of the  growth  of CFU-MK,  BFU-E,  and 
CFU-GEMM  for the  alIbtk  mice,  whereas the nontrans- 
genic littermates were normal. Only GM-CFC were observed 
in the BM cultures of GCV-treated cfllbtk animals. Leakage 
of tk phosphorylated  metabolites from the primary  tk ex- 
pressing cells, i.e., those of the megakaryocytic lineage, could 
account for the erythroid effect, i.e.,  a bystander effect on 
neighboring cells as described by others (34, 35). However, 
this would seem a most unlikely explanation given the clear 
demonstration that the effect was completely limited to mega- 
karyocytic and erythroid lineages while GM-CFC were main- 
tained. 
Different hypotheses can be proposed to explain the per- 
sistence of normal  granulomonocytopoiesis despite the ab- 
sence of multipotent progenitors. The alIb gene may be ex- 
pressed  at  the  level  of  CFU-GEMM,  resulting  in  the 
eradication of mixed colonies of all kinds.  This would have 
to assume that GM-CFC are derived from a totipotent stem 
cell via an alternative and direct pathway of differentiation. 
This is consistent with a model for hematopoiesis that pro- 
poses a random commitment  of a strictly multipotent  to a 
monopotent  stem cell (36)  and is  supported by data  from 
Fraser et al. (37), demonstrating that rabbit antiserum against 
human platelets was also significantly toxic to human CFU- 
GEMM.  Its validity is questioned, however, by the finding 
that the message for odlb was not found in human CD34 + 
cells treated with mafosfamide, which spared quiescent early 
stem cells  while killing  stem cells  in cycle (17). 
An  alternative  hypothesis is that  the  odlbtk  gene is ex- 
pressed  either  at  the  stage of a restricted  erythroid-mega- 
karyocytic (EM) stem cell or at the level of the monopotent 
2147  Tronik-Le  Roux et al. Table  1.  Effect of GCV  Treatment  on Blood Cell  Counts 
Control  mouse  otlIbtk mouse 
DO  D10  D23  DO  D10  D23 
10.91  +  2.3  10.93  +  1.13  10.88  +  0.5  10.69  +  3.053  9.23  +  0.59  3.12  +  0.88 
10.19  +  1.5  12.33  +  4.0  13.00  _+  1.0  8.33  -  4.27  8.15  +  1.65  13.59  _+  14.08 
0.80  -+ 0.09  0.93  +  0.18  0.77  ++. 0.14  0.73  +  0.12  0.045  +  0.012  0.02  +_  0.007 
Mean peripheral blood cell counts (_+  SD) of control and transgenic otllbtk mice (n  =  5) before (DO). 10 d (DIO), or 23 d (D23) of GCV (0.05 
mg/g per d) treatment.  The counts shown are per liter of blood volume. 
erythroid BFU-E and CFU-MK.  In this case, as soon as an 
erythroid or a megakaryocytic cell component differentiates 
into any type of mixed colony, it would be eradicated by the 
toxic effect of GCV, resulting in the selection of only granu- 
Iomonocytic cells. This assumption is consistent with a model 
that supports the differentiation of multipotent progenitors 
through a stochastic and progressive restriction in cell lineages 
(5, 38). The existence of a bipotent EM stem cell in the mouse 
BM has been demonstrated by cell culture experiments using 
a sexual marker (39) and from studies on the effects of high 
doses of EPO on murine EM progenitors (40).  In addition, 
most human leukemic megakaryocytic cell lines exhibit con- 
comitant erythroid markers such as globin and glycophorin 
A  (41, 42) or transcriptional  factors such as GATA-1, which 
acts in combination with other factors to control alIb pro- 
moter activity (43-45).  Finally,  the expression  of the odlb 
in separate committed progenitors CFU-MK and BFU-E is 
also supported by other published work. Berridge et al. (46) 
reported that the preincubation of mouse BM cells with com- 
plement  and rabbit  anti-mouse  platelet  serum,  containing 
anti-czlIb~3 antibodies, inhibited the growth of spleen colo- 
nies (CFU-S)  as well as those of CFU-MK in vitro.  Other 
studies have shown that the otlIb gene is expressed in human 
erythroleukemic cells (47)  and Okumura  et al.  (48),  using 
immunocytochemistry  to detect  cxlIbB3,  demonstrated  its 
presence in one of the two daughter cell doublets, resulting 
from the division  of a  single  stem  cell,  whereas  the other 
developed into BFU-E  in semisolid culture.  Thus,  there is 
ample evidence that  the expression of the cdlbB3  is main- 
tained during megakaryocyte and platelet production and is 
turned off in late erythroid differentiation.  A  repressor ele- 
ment, active in erythroid cells and recently described in the 
IIb promoter (49), might be responsible for the final tissue- 
specific expression of this gene in megakaryowtes and platelets. 
Although  the fragment of the otlIb promoter  used in our 
experiments contained this repressor element, we cannot ex- 
clude the possibility that other unknown sequences, required 
for a restricted megakaryocytic expression, might be absent. 
Table 2.  Number of GM-CFC,  BFU-E,  and CFU-MK in In- 
dividual Semisolid Assays from BM Cells of Control and crllbtk 
Mice  Treated with  GCV 
GM-CFC  BFU-E  CFU-MK 
50. 
..d 
J  ~  o 
NUMBER OF DAYS AFTER GCV WITHDRAWAL 
150- 
100" 
Figure  6.  Effect  of cytokine administration on thrombocytopenia in 
GCV-treated transgenic mice. Transgenic mice were treated with GCV 
(0.05 mg/d per g i.p.) to produce stable thrombocytopenia. The effect 
on platelet number of concurrent treatment with IL-6 (0) and Ib11 (A) 
compared with untreated thrombocytopenic control animals (X) is shown. 
The dose of IL-6/IL-11 was 0.008 g/g per d. 
Experiment  1 
Control  15  +  2  13  +  2  10  +  2 
cdlb-tk  transgenic  10  +  1  0.3  _+  0.1  0 
Experiment 2 
Control  42  +  2  16  _+  6  44  _+  9 
allb-tk  transgenic  43  _+  4  1.5  +  1  6  +_  1 
Experiment 3 
Control  38  +  5  13  _+  3  30  +  8 
czlIb-tk transgenic  23  +  4  1  _+  1  0 
Marrow cells (5  x  104 per well) from control and otllbtk mice treated 
with GCV (1 mg/d for 10 ds) were cultured in 0.25 ml complete IMDM 
supplemented with predetermined optimal concentrations of cytokines 
as described in Materials and Methods. GM-CFC and BFU-E were cul- 
tured in methyl-cellulose and counted after 7 d of incubation under the 
inverted microscope. CFU-MK were cultured in agar for 7 d and iden- 
tified after desiccation of the gel and specific  staining for acetylcholinester- 
ase. Each number ( _+ SD) are the mean of three wells in three different 
experiments. 
2148  Transgenic  Mice with Reversible Thrombocytopenia Table 3.  Number of Monopotent and Mixed Myeloid Colonies  from BM Cells of Control and crlIbtk Mice Treated with GCV 
GEM  +  GEMK 
GM-CFC  BFU-E  MK  BFU-E-MK  +  GMMK  GEMMK 
1  64  _+11.5  12  -+  1.8  4  +  1.7  4.5  +  1.1  8.5  _+  3.6  2.2  _+  0.8 
61  _+  3.3  0.6  -+ 0.5  1.4  +  0.9  0.6  _+ 0.9  1.6  _+  1.5  0.4  _+  0.5 
2  71  _+  8.5  8  _+  3.3  9 +  2.2  2.2  _+  0.8  4  _+  1.6  2.2  +  1 
59  _+  7.4  0.75  -+ 0.5  0.25  +  0.5  0  0  0 
Marrow cells (5  x  10a/ml  per dish) from control and otlIbtk mice treated with GCV (1 mg/d for 10 d) were obtained  by femoral aspiration and 
plated in 1 ml of culture medium as described in Materials and Methods. The number of colonies was the mean SD of five identical  dishes. Mixed 
colonies consisted  of bilineage BFU-E-MK (erythroid  and megakaryocytic),  trilineage  GEM (granulocytic  erythroid  macrophagic), GEMK  (granulo- 
cytic erythroid  megakaryocytic),  GMMK (granulocytic  macrophagic  megakaryocytic),  and multipotent  GEMMK  (granulocytic  erythroid  macrophagic 
and megakaryocytic). 
It is also possible  that the effect noted on erythroid pro- 
genitors may reflect a secondary effect of adrenal suppression 
given the demonstration that the message for tk was also 
found in this tissue.  Thus it would be possible  that, after 
GCV treatment, tk toxicity of adrenal cells may occur resulting 
in the loss of hormonal output and a secondary suppression 
of hematopoietic activity. Although hormone levels were not 
measured, there was no evidence of adrenal atrophy. Moreover, 
given the relatively slow turnover of adrenal relative to he- 
matopoietic cells, such an effect would appear most unlikely. 
The biological activity of thrombopoietin, the hormone 
that specifically promotes the proliferation and maturation 
of megakaryocytes, is mediated by a specific receptor encoded 
by the c-rnpl protooncogene (50-53).  The effects of c-mpI 
knockout in mice have been reported recently (54). Although 
exhibiting  severe and  irreversible  thrombocytopenia,  the 
animals were otherwise healthy. The fact that they were not 
totally thrombocytopenic (15%  of normal platelet count), 
suggests that, in addition to c-mpl expression, other factors 
are required for the complete development and maturation 
of the megakaryocytic  lineage. The present study demonstrates 
that a severe thrombocytopenia may be produced on demand 
by the administration of GCV to odlbtk transgenic mice. 
Moreover, this effect may be completely reversed by the removal 
of the inciting treatment. Consequently, this model allows 
the study of the megakaryocyte lineage by providing the means 
by which the kinetics of differentiation and maturation may 
be modified to order and at a given point in time of lineage 
development. It should also be possible  to use this method 
to target other genes that may modify the activity of the 
cell in different ways and promote the synthesis of factors 
that may modify megakaryocyte maturation and/or function 
subsequently. 
The model may also be used to study potential therapeutic 
interventions in the management of thrombocytopenic dis- 
orders since the duration of GCV treatment may be used to 
dissociate,  in large part,  the effect on thrombopoiesis over 
erythropoiesis. For example, in preliminary studies reported 
here, it was demonstrated that the rate of  recovery from throm- 
bocytopenia could be modulated by the administration of 
cytokines to the thrombocytopenic animals.  These studies 
support the view that this model may have pharmacological 
relevance in addressing such issues  in vivo. 
Platelets  are directly or indirectly involved  in a number 
of vascular diseases, including thrombosis, coronary artery 
restenosis,  and atherosclerosis.  A number of different trans- 
genic mouse models with an atherosclerotic phenotype have 
recently been developed (55, 56). Thus, using this approach, 
it is now feasible to create a second generation of atherosclerotic 
animals with controlled thrombopoiesis. Similarly,  the role 
of platelets in arterial  restenosis is still unclear.  A model for 
arterial injury in the mouse has been reported recently (57). 
Its use in transgenic animals such as those described here would 
facilitate the study of  whether or not adequate platelet numbers 
influence the outcome of vascular  insult. 
In conclusion, the c~Ilbtk  mice described in the present 
study afford a particularly flexible system for inducing throm- 
bocytopenia on demand. This should prove suitable both for 
deciphering the fundamental mechanisms that underlie throm- 
bocytopoiesis and also for the study of vascular occlusive dis- 
eases, where it has been suggested that platelets may play 
a significant pathogenetic role. 
All the animal studies reported were performed in accor- 
dance with current French government regulations (Services 
V&6rinaires de la Sant6 et de la Production Animale, Minist~re 
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